Mucorales infections have recently re-emerged as serious, life-threatening (B80% mortality) opportunistic complications in patients with leukemia, severe prolonged granulocytopenia, and in recipients of allogeneic hematopoietic stem cell transplants (HSCT).
1,2 High-dose amphotericin B, surgical excision of necrotic infected tissue when possible, and most importantly, restoration of immune dysfunction are critical for satisfactory resolution of infection. Treatment options for patients unable to receive amphotericin B are limited, albeit preliminary clinical experience with the investigational agent posaconazole (SCH-56592) was recently reported as promising. 3 We present a patient with pulmonary zygomycosis, who developed nephrotoxicity with polyene-based antifungal therapy and responded to inhaled amphotericin B.
A 61-year-old man with refractory chronic lymphocytic leukemia (CLL) developed fever, productive cough, and modest respiratory distress while receiving salvage therapy (IDEC-152, a monocolonal antibody to CD23). Prior therapy included chlorambucil, fludarabine and cyclophosphamide. At 30 months prior to presentation, he underwent allogeneic nonmyeloablative stem cell transplantation from a HLA-identical donor. Pre-transplant conditioning consisted of fludarabine (30 mg/m 2 ), cyclophosphamide (750 mg/m 2 ), each given daily for 3 days. In addition, rituximab (375 mg/m 2 ) was given 13 days prior to stem cell transfusion, followed by 1000 mg/m 2 in weekly three doses. At 16 months post transplant, the patient received donor lymphocyte infusion for persistent disease; this was complicated by graft-versus-host diseases of skin and gastrointestinal tract, and responded to systemic corticosteroid therapy.
At 23 months following transplant, the patient had sinopulmonary infection due to respiratory syncytial virus, Mycobacterium chelonei abscessus, and presumed invasive pulmonary aspergillosis, which responded to 4 months of caspofungin therapy. Treatment with caspofungin was continued and 4 weeks prior to presentation the daily dose was changed to 50 mg three times weekly. A diagnostic bronchoalveolar lavage (BAL) was performed to evaluate new right lower lobe infiltrates (Figure 1a ) and the caspofungin dose was increased (100 mg daily). Pseudallescheria boydii and Rhizomucor were isolated from BAL culture samples. The P. boydii pneumonia responded favorably to high-dose caspofungin, treatment with amphotericin B was not given due to prior history of druginduced renal dysfunction. After 1 week, caspofungin dose was lowered to 50 mg daily.
After 4 weeks, he had persistent cough, and bronchial cast expectorant; a new noncontiguous right lower lobe lung lesion was seen on repeat CT scan of the chest (Figure 1c) although the right supra-diaphragmatic Pseudallescheria probable pneumonia had nearly resolved (Figure 1b) . A trial of low-dose liposomal amphotericin B (3 mg/kg daily) was unsuccessful due to rapid increase in serum creatinine levels (B1 mg/dl increase). Treatment with aerosolized amphotericin B lipid complex (50 mg daily via RespiGuard-II nebulizer) was commenced. After 3 weeks of inhaled amphotericin B lipid complex therapy, resolution of cough was accompanied by radiographic recovery (Figure 1d ). He has tolerated inhaled antifungal therapy for 5 months with no serious untoward effects. During this therapy, no recurrence of polyfungal pneumonia occurred, even though the patient remained severely immunosuppressed.
Pulmonary zygomycosis in oncology patients is a serious complication; clinical recovery is uncommon, despite optimum antifungal therapy in most individuals with systemic Mucorales disease.
1,2 Ecchinocandin-pneumocandin analogues have provided alternative treatment options for patients with amphotericin B-nonsusceptible mold infections including P. boydii, Scedosporium apiospermum, Paecilomyces and dematiaceous (black wall) fungi. [4] [5] [6] However, suboptimum efficacy of these compounds against most organisms associated with human zygomycosis pose a Figure 1 Noncontrast enhanced computed tomography scan of the chest.
(a) Right lower lung lobe, supra-diaphragmatic infiltrate, 'halo sign' is also noted (arrow); (b) At 4 weeks after therapy, near-complete resolution of primary Pseudallesheria pneumonia is noted (arrowhead), whereas (c) a new dense, pleural-based lesion is observed in the proximal lateral right lower lobe (arrow). (d) A near-complete resolution of probable pulmonary zygomycosis after a 3-week aerosolized amphotericin B lipid complex therapy (arrowhead). significant problem in providing extended-spectrum antifungal therapy that is often given pre-emptively or empirically to patients during high-risk periods.
Recently, a result of open-label study with posaconazole (SCH-56 592) in 23 patients with refractory primary zygomycosis was presented. 3 Among these 23 individuals, 61% had hematological malignancy and 48% were recipients of hematopoietic stem cell transplants. An overall successful outcome in 70% of mostly high-risk cancer with refractory zygomycosis was encouraging. However, posaconazole (SCH-56592) is not approved by the FDA.
Prophylactic use of aerosolized amphotericin B deoxycholate in recipients of heart transplant 7 and aerosol amphotericin B lipid complex in patients undergoing lung transplantation 8 has demonstrated no serious untoward effects, and lead to a significant reduction in the rate of pulmonary mycosis. However, this method of drug delivery has not been explored in treatment of established fungal lung disease. This case demonstrates a successful outcome with aerosolized amphotericin B lipid complex in a patient with intolerance to systemic liposomal amphotericin. The lack of significant side effects with the aerosolized agent should lead to increased consideration of such therapy in patients with poor tolerance or progressive pneumonia despite appropriate conventional antifungal therapy.
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